Yes to an extent as the price that will ultimately be able to be charged will be dependent on many factors including how well bisantrene works as a cardioprotective anticancer agent. Of course as investors you need to have some idea of the likely pricing, so this is why we shared the Triangle report.
I should mention that the Triangle report was from primary market research undertaken for internal purposes as we want to ensure that we developed bisantrene in a way that met a true large-scale market need. It is all too easy to just focus on the science and end up developing a drug that has a very limited market. Decision made early in development can make or break the commercial success of a new drug. Making sure you get the positioning of your drug right is difficult and even the largest pharma companies struggle with this process.
- Forums
- ASX - By Stock
- Ann: Race releases complete cardio-protection data & video
Yes to an extent as the price that will ultimately be able to be...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.64 |
Change
-0.100(5.76%) |
Mkt cap ! $278.5M |
Open | High | Low | Value | Volume |
$1.71 | $1.71 | $1.64 | $205.3K | 123.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1526 | $1.64 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.65 | 234 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1526 | 1.635 |
3 | 7309 | 1.620 |
2 | 25621 | 1.610 |
7 | 6929 | 1.600 |
1 | 2000 | 1.580 |
Price($) | Vol. | No. |
---|---|---|
1.645 | 234 | 1 |
1.680 | 1785 | 1 |
1.700 | 15500 | 1 |
1.725 | 6000 | 1 |
1.735 | 6000 | 1 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online